ReviewDrugs2021
Understanding the Chameleonic Breakthrough Cancer Pain.
Review in Drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Inverse dose proportionality: using breakthrough pain medication as a biological indicator for background analgesia escalation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- A scoping review of breakthrough cancer pain: mapping the evidence landscape.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- A scoping review of breakthrough cancer pain: Multidimensional patient needs and influencing factors.Asia-Pacific journal of oncology nursing · 2025Review
- Once again... breakthrough cancer pain: an updated overview.Journal of anesthesia, analgesia and critical care · 2023Review
- Cancer Pain Management: A Narrative Review of Current Concepts, Strategies, and Techniques.Current oncology (Toronto, Ont.) · 2023Review
- Breakthrough pain among cancer patients at oncology units in Northern Ethiopia; a multi-center study.Frontiers in oncology · 2023Article
- Review
- Cancer pain is over! (If you want it).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- A Longitudinal Study of Breakthrough Cancer Pain: An Extension of IOPS-MS Study.Journal of clinical medicine · 2021Article
- The Prevalence and Characteristics of Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain.Cancers · 2021Article
- Chronic Pain Treatment and Digital Health Era-An Opinion.Frontiers in public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breakthrough cancer pain (BTcP) is a variegated phenomenon, that often presents in different ways in each individual, and may change its presentation in the same individual during the course of disease. An appropriate assessment is fundamental for depicting the pattern of BTcP in individuals. This information is determinant for a personalised management of BTcP. The use of opioids as needed, is recommended for the management of BTcP. There are several options which should be chosen according to the individual pattern of BTcP. In general, a drug with a short onset and offset should be preferred. Although oral opioids may still have specific indications, fentanyl products have been found to be more rapid and effective, providing analgesia in 5-15 min. The most controversial point regards the opioid dose to be used. The presence of tolerance suggests using a dose that is proportional to the dose used for background analgesia. In contrast, regulatory studies have suggested using the minimal available dose to be titrated until the effective dose. Further large studies should definitely settle this never-ending question.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.